Kiadis Pharma announces res­ig­na­tion of Robbert van Heekeren and appoints Scott A. Holmes as new Chief Financial Officer

Amsterdam, The Netherlands, August 30, 2018 – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clin­i­cal-stage bio­phar­ma­ceu­ti­cal com­pa­ny, today announces that Robbert van Heekeren is step­ping down as Chief Financial Officer, or CFO, and as mem­ber of the Management Board. Scott A. Holmes has been appoint­ed as new CFO. Mr. Holmes, who cur­rent­ly serves as Senior Vice President and CFO at Keryx Biopharmaceuticals, will join the Company fol­low­ing the com­ple­tion of Nasdaq-list­ed Keryx Biopharmaceuticals’ recent­ly announced merg­er with Akebia Therapeutics, which is expect­ed to close by the end of 2018.

Mark Wegter, Chairman of the Supervisory Board of Kiadis Pharma, com­ment­ed: “I respect Robbert’s deci­sion to pur­sue his career in anoth­er direc­tion and would like to express my sin­cere grat­i­tude for his tremen­dous con­tri­bu­tions and com­mit­ment to Kiadis Pharma dur­ing his 10 years with the Company, includ­ing the suc­cess­ful IPO on Euronext in 2015, and wish him every suc­cess in his future endeav­ors.

Robbert van Heekeren, com­ment­ed: “My deci­sion to leave Kiadis was dif­fi­cult, as I’ve been part of the jour­ney from a small pri­vate enti­ty to a pub­lic, near-com­mer­cial growth com­pa­ny. However, I feel con­fi­dent I leave Kiadis in a great shape, with a strong suc­ces­sor to my role, and I wish Scott every suc­cess as new CFO.

Arthur Lahr, CEO of Kiadis Pharma, com­ment­ed: “I would like to thank Robbert for his sup­port and con­tri­bu­tion to the growth of Kiadis. Together with the Board, we have car­ried out a thor­ough search for a Chief Financial Officer and I’m delight­ed to wel­come Scott to Kiadis. Scott’s expe­ri­ence with lead­ing the finance func­tions in com­mer­cial-stage biotech­nol­o­gy com­pa­nies, as well as his track record in rais­ing sig­nif­i­cant cap­i­tal for pub­licly list­ed com­pa­nies will strength­en our lead­er­ship team, and allows us to fur­ther build our U.S. pres­ence.

Incoming Chief Financial Officer, Scott A. Holmes, com­ment­ed: “I’m excit­ed to join Kiadis Pharma at this cru­cial time in the Company’s evo­lu­tion. As the Company approach­es the poten­tial approval and com­mer­cial­iza­tion of its lead prod­uct can­di­date, ATIR101, I look for­ward to col­lab­o­rat­ing with Arthur, the man­age­ment team and the Supervisory Board to build a lead­ing ful­ly-inte­grat­ed bio­phar­ma­ceu­ti­cal com­pa­ny.

Mr. Holmes brings near­ly 20 years of life sci­ences and finan­cial man­age­ment exper­tise to Kiadis Pharma. Prior to Keryx, he was Senior Vice President of finance, investor rela­tions and trea­sur­er at AMAG Pharmaceuticals, dur­ing a peri­od of high growth dri­ven by acqui­si­tions and pub­lic financ­ings. Prior to this he held senior roles at Molecular Biometrics, On-Q-ity and Dynogen. Mr. Holmes start­ed his career at Ernst & Young, in both the Assurance and Transaction Services prac­tices, and while at Ernst & Young he earned his Certified Public Accountant cer­tifi­cate in the Commonwealth of Massachusetts. He holds a MS/MBA degree from Northeastern University and a BA in History from Middlebury College.

Mr. Holmes will be based in Boston and respon­si­ble for Kiadis Pharma’s finance and investor rela­tions func­tions. He will join the Company’s man­age­ment team, report­ing to the Chief Executive Officer. Kiadis will pro­pose to a future share­hold­ers’ meet­ing that Mr. Holmes be appoint­ed to the Management Board.

Transition arrange­ments have been made includ­ing hand over between the incom­ing and out­go­ing CFO and the inter­im appoint­ment of Paul van Hagen to the Amsterdam-based finance func­tions. Mr. van Hagen has broad expe­ri­ence with pub­licly-list­ed com­pa­nies. He was pre­vi­ous­ly Senior Director of Finance & Control at Prosensa and BioMarin, Director Group Reporting and Financial Control at Crucell and Senior Manager Audit at Ernst & Young.

Leave a Reply

Your email address will not be published. Required fields are marked *